J Korean Med Sci.  2022 Mar;37(10):e80. 10.3346/jkms.2022.37.e80.

A Retrospective Population-Based Survival Study of Idiopathic Pulmonary Arterial Hypertension in Korea

Affiliations
  • 1Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 2Division of Cardiology, Department of Pediatrics, Adult Congenital Heart Clinic, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Abstract

Background
Few studies used nationwide data to assess the survival rates (SRs) and death risk for idiopathic pulmonary arterial hypertension (IPAH; ICD-10 I27.0) in Korea.
Methods
IPAH data (N = 9,017; female:male = 6:4) were collected from the National Health Insurance Service in Korea, from 2006 through 2017. The data consisted of primary diagnoses related to IPAH. The Kaplan–Meier method and Cox proportional-hazards analyses were carried out.
Results
The mean age was 62.3 (± 19.4) years, 64.2 (± 18.9) years in female and 59.4 (± 19.8) years in male (P < 0.001). The one-, three-, five- and 10-year SRs for IPAH were 89.0%, 79.8%, 72.3% and 57.0%, respectively. The adjusted hazard ratio (HR) of IPAH was 1.81 (95% confidence interval [CI], 1.26–2.59) in 60–69 age group, 3.42 (95% CI, 2.40–4.87) in 70–79, and 7.73 (95% CI, 5.43–11.0) in 80s. Other risk factors were male, low-income status, diabetes, myocardial infarction, atrial fibrillation, ischemic stroke, hemorrhagic stroke, and malignant neoplasm.
Conclusion
The 10-year SR of IPAH was 57% in Korea. The HR for IPAH was significantly high in patients with older age and other risk factors.

Keyword

Survival Rates; Death; Risk; Causes of Death; Idiopathic Pulmonary Arterial Hypertension

Figure

  • Fig. 1 Survival curve of idiopathic pulmonary arterial hypertension (IPAH) in Koreans. (A)Survival rates overall and by sex and (B) by age group.


Reference

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25):Suppl. D34–D41. PMID: 24355639.
Article
2. National Health Insurance Sharing Service. Updated 2022. Accessed June 25, 2010. https://nhiss.nhis.or.kr/bd/ab/bdaba011eng.do .
3. Jang SY, Park TK, Kim DK. Survival and causes of death for Takayasu’s arteritis in Korea: a retrospective population-based study. Int J Rheum Dis. 2021; 24(1):69–73. PMID: 33089946.
Article
4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012; 142(2):448–456. PMID: 22281797.
Article
5. Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, et al. The giessen pulmonary hypertension registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017; 36(9):957–967. PMID: 28302503.
Article
6. Escribano-Subias P, Blanco I, López-Meseguer M, Lopez-Guarch CJ, Roman A, Morales P, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012; 40(3):596–603. PMID: 22362843.
Article
7. Skride A, Sablinskis K, Lejnieks A, Rudzitis A, Lang I. Characteristics and survival data from Latvian pulmonary hypertension registry: comparison of prospective pulmonary hypertension registries in Europe. Pulm Circ. 2018; 8(3):2045894018780521. PMID: 29767576.
Article
8. Strange G, Lau EM, Giannoulatou E, Corrigan C, Kotlyar E, Kermeen F, et al. Survival of idiopathic pulmonary arterial hypertension patients in the modern era in Australia and New Zealand. Heart Lung Circ. 2018; 27(11):1368–1375. PMID: 29029950.
Article
9. Ogawa A, Satoh T, Tamura Y, Fukuda K, Matsubara H. Survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension. Am J Cardiol. 2017; 119(9):1479–1484. PMID: 28267959.
Article
10. Fischler M, Speich R, Dorschner L, Nicod L, Domenighetti G, Tamm M, et al. Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly. 2008; 138(25-26):371–378. PMID: 18587689.
11. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343–349. PMID: 1863023.
12. Chun KJ, Kim SH, An BJ, Kim SH, Ha JK, Hong TJ, et al. Survival and prognostic factors in patients with primary pulmonary hypertension. Korean J Intern Med. 2001; 16(2):75–79. PMID: 11590905.
Article
13. Song S, Lee SE, Oh SK, Jeon SA, Sung JM, Park JH, et al. Demographics, treatment trends, and survival rate in incident pulmonary artery hypertension in Korea: a nationwide study based on the health insurance review and assessment service database. PLoS One. 2018; 13(12):e0209148. PMID: 30566510.
Article
14. Lee WT, Ling Y, Sheares KK, Pepke-Zaba J, Peacock AJ, Johnson MK. Predicting survival in pulmonary arterial hypertension in the UK. Eur Respir J. 2012; 40(3):604–611. PMID: 22556026.
Article
15. Santos M, Gomes A, Cruz C, Rocha J, Ricardo M, Gonçalves F, et al. Long-term survival in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Insights from a referral center in Portugal. Rev Port Cardiol (Engl Ed). 2018; 37(9):749–757. PMID: 30144959.
Article
16. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011; 124(19):2145–2154. PMID: 22064958.
Article
17. Shin HY, Lee JY, Song JH, Lee SM, Lee JH, Lim BS, et al. Cause-of-death statistics in the Republic of Korea,2014. J Korean Med Assoc. 2016; 59(3):221.
Article
18. Jang SY, Huh J, Kim EK, Chang SA, Song J, Kang IS, et al. Impact of atrial fibrillation on survival in adults with congenital heart disease: a retrospective population-based study. J Korean Med Sci. 2021; 36(5):e43. PMID: 33527785.
Article
19. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019; 156(2):323–337. PMID: 30772387.
Article
20. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164–172. PMID: 20585012.
Article
21. Chung WJ, Park YB, Jeon CH, Jung JW, Ko KP, Choi SJ, et al. Baseline characteristics of the Korean registry of pulmonary arterial hypertension. J Korean Med Sci. 2015; 30(10):1429–1438. PMID: 26425039.
Article
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr